D007 Acute Lymphoblastic Leukemia - Now with Extended Coverage

Acute Lymphoblastic Leukemia (ALL) is an aggressive childhood blood cancer that affects T- and B-cells. Genetic alterations in the different subtypes of ALL are well characterized and have been suggested to be outcome predictors in ALL. 

Based on our latest technology, SALSA^® digitalMLPA™ Probemix D007 Acute Lymphoblastic Leukemia is a new generation panel that targets 73 genes and 8 regions that are altered in ALL, enabling the simultaneous detection of numerous ALL-related alterations with just a single reaction. These include intragenic copy number alterations (CNAs), intrachromosomal gene fusions, partial chromosome gains, losses and amplifications, and gross ploidy changes. 

D007 Acute Lymphoblastic Leukemia just received an update, with version B1 featuring new probes that increase the coverage of ALL-relevant regions and target genes of emerging interest for ALL. For an overview of the genes targeted, see the flyer.

With a turnaround time of only 48-72 hours and with as little as 20 ng of DNA input per reaction, SALSA^® digitalMLPA™ is the ground-breaking technology that combines the high sensitivity of MLPA with the broad coverage of Next Generation Sequencing, making the investigation of ALL-relevant genetic alterations straightforward and accessible.

digitalMLPA assays are compatible with all Illumina sequencing platforms, and the data can be analysed using our free, easy-to-use proprietary Coffalyser digitalMLPA™ software.